Completed PHASE3 INTERVENTIONAL 1-arm NCT01964560

A Clinical Study to Investigate the Efficacy and Safety of Lacosamide as an Add on Therapy in Children With Epilepsy With Partial-onset Seizures

A Multicenter, Open-label, Long-term Extension Study to Investigate the Efficacy and Safety of Lacosamide as Adjunctive Therapy in Pediatric Subjects With Epilepsy With Partial-Onset Seizures

Sponsor: UCB BIOSCIENCES, Inc.

Conditions Epilepsy

Interventions Lacosamide

Updated 38 times since 2017 Last updated: Sep 30, 2022 Started: Aug 13, 2014 Primary completion: Apr 13, 2022 Completion: Apr 13, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Epilepsy, this trial is completed. The trial is conducted by UCB BIOSCIENCES, Inc. and has accumulated 38 data snapshots since 2014. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

38 versions recorded

Oct 2025 — Present [monthly]

Completed PHASE3
Sep 2025 — Oct 2025 [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Nov 2022 — Jul 2024 [monthly]

Completed PHASE3

▶ Show 33 earlier versions

Sep 2022 — Nov 2022 [monthly]

Completed PHASE3
Jul 2022 — Sep 2022 [monthly]

Completed PHASE3

Status: Active Not Recruiting → Completed
May 2022 — Jul 2022 [monthly]

Active Not Recruiting PHASE3
Apr 2022 — May 2022 [monthly]

Active Not Recruiting PHASE3
Jan 2022 — Apr 2022 [monthly]

Active Not Recruiting PHASE3
Sep 2021 — Jan 2022 [monthly]

Active Not Recruiting PHASE3
Jun 2021 — Sep 2021 [monthly]

Active Not Recruiting PHASE3
Mar 2021 — Jun 2021 [monthly]

Active Not Recruiting PHASE3
Feb 2021 — Mar 2021 [monthly]

Active Not Recruiting PHASE3
Jan 2021 — Feb 2021 [monthly]

Active Not Recruiting PHASE3
Dec 2020 — Jan 2021 [monthly]

Active Not Recruiting PHASE3
Sep 2020 — Dec 2020 [monthly]

Active Not Recruiting PHASE3
Aug 2020 — Sep 2020 [monthly]

Active Not Recruiting PHASE3
Jul 2020 — Aug 2020 [monthly]

Active Not Recruiting PHASE3

Status: Enrolling By Invitation → Active Not Recruiting
Jan 2020 — Jul 2020 [monthly]

Enrolling By Invitation PHASE3
Nov 2019 — Jan 2020 [monthly]

Enrolling By Invitation PHASE3
Oct 2019 — Nov 2019 [monthly]

Enrolling By Invitation PHASE3
Apr 2019 — Oct 2019 [monthly]

Enrolling By Invitation PHASE3
Jan 2019 — Apr 2019 [monthly]

Enrolling By Invitation PHASE3
Dec 2018 — Jan 2019 [monthly]

Enrolling By Invitation PHASE3
Nov 2018 — Dec 2018 [monthly]

Enrolling By Invitation PHASE3
Sep 2018 — Nov 2018 [monthly]

Enrolling By Invitation PHASE3
Jul 2018 — Sep 2018 [monthly]

Enrolling By Invitation PHASE3
Jun 2018 — Jul 2018 [monthly]

Enrolling By Invitation PHASE3
May 2018 — Jun 2018 [monthly]

Enrolling By Invitation PHASE3
Mar 2018 — May 2018 [monthly]

Enrolling By Invitation PHASE3
Nov 2017 — Mar 2018 [monthly]

Enrolling By Invitation PHASE3
Aug 2017 — Nov 2017 [monthly]

Enrolling By Invitation PHASE3
Jun 2017 — Aug 2017 [monthly]

Enrolling By Invitation PHASE3
May 2017 — Jun 2017 [monthly]

Enrolling By Invitation PHASE3
Mar 2017 — May 2017 [monthly]

Enrolling By Invitation PHASE3
Feb 2017 — Mar 2017 [monthly]

Enrolling By Invitation PHASE3
Jan 2017 — Feb 2017 [monthly]

Enrolling By Invitation PHASE3

First recorded

Aug 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

UCB BIOSCIENCES, Inc.
UCB Biopharma SRL

Data source: UCB Pharma

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aguascalientes, Mexico , Athens, Greece , Bangkoknoi, Thailand , Bardejov, Slovakia , Beijing, China , Belgrade, Serbia , Birmingham, United States , Brussels, Belgium , Bucharest, Romania , Budapest, Hungary and 102 more locations